Table 3.
Agent name | Targeting cancer | Anticancer function | Reference |
---|---|---|---|
Natural products | |||
Andrographolide | Breast cancer | Antiangiogenesis | Dai et al.93 |
Diallyl disulfide | Gastric cancer | Inhibit migration and invasion | Su et al.135 |
EGCG | Breast cancer | Inhibit invasion | Deb et al.136 |
Arctigenin | Prostate cancer | Inhibit tumor growth | Wang et al.137 |
Mithramycin A | Lung cancer | Inhibit metastasis | Lin et al.138 |
Synthetic products | |||
NucAnt 6L | Melanoma | Inhibit invasion | Destouches et al.140 |
p700 | Breast cancer | Inhibit tumor growth and angiogenesis | Chen et al.141 |
lncRNA | Diffuse large B-cell lymphoma | Induce apoptosis and inhibit tumor growth | Su et al.142 |
TAPI-0 | AML | Inhibit AML cell-induced STNK cell abnormalities | Arriga et al.143 |
Epigenetic agents | |||
SGI-1027 | Multiple cancers | Block DNMT1 and reactivate TIMP-3 | Datta et al.144 |
MPT0G013 | Colon cancer | Inhibit angiogenesis, tumor growth, metastasis | Wang et al.145 |
decitabine | AML | Enhance the lytic activity of NK cells | Raneros et al.131 |
DNMT1, DNA methyltransferase 1; EGCG, epigallocatechin-3-gallate; NK, natural killer; p700, synthetic peptide derived from N-terminal domain of TIMP-3; STNK, short-term natural killer.